Research findings regarding the “Diagnostic Kit for Biomarkers Predicting the Efficacy of Neoadjuvant Chemotherapy (NAC-GS) for Pancreatic Cancer,” a project led by our CEO, Keisuke Taniuchi (Associate Professor, Department of Gastroenterology, Kochi University School of Medicine), have been featured on the website of the Center for Future Medicine, Department of Future Medical Development, Osaka University Hospital.

■ Background and Research Overview

Currently, for pancreatic cancer that is surgically resectable, “neoadjuvant chemotherapy”—which involves administering chemotherapy before surgery (NAC-GS therapy) to control the cancer before proceeding with surgery—is one of the standard treatments.
However, neoadjuvant chemotherapy is not effective for all patients, and the risk of missing the optimal timing for surgery when no effect is observed remains a challenge.

■ Key Points of the Technology Featured

A research group led by Dr. Taniuchi has developed a diagnostic kit that can predict with high accuracy whether preoperative chemotherapy will be effective before treatment begins by measuring biomarkers in biopsy samples collected for diagnostic purposes.

Realizing Personalized Medicine:

It enables us to develop the optimal treatment strategy for each individual patient.

Minimally invasive examination:

Since we use pancreatic cancer tissue that has already been collected for diagnostic purposes, the burden on the patient is kept to a minimum.

Improved treatment outcomes:

This serves as a basis for decision-making to ensure that patients who are eligible for surgery and are likely to benefit from preoperative chemotherapy receive the appropriate treatment, while allowing for the selection of early surgery or alternative treatments when such benefits are not expected.
This initiative is highlighted as a key outcome of the center’s “translational research,” representing a crucial step in the collaboration between academia, medical institutions, and industry to bring cutting-edge medical technologies into practical use (social implementation).

Page URL

For more details, please visit the introduction page for the Center for Future Medicine at Osaka University Hospital via the link below.

[In Vitro Diagnostic Reagent] Diagnostic Kit for Biomarkers Predicting the Efficacy of Neoadjuvant Chemotherapy (NAC-GS) in Pancreatic Cancer (In Japanese Language)

Osaka University Hospital, Department of Future Medical Development, Future Medical Center Website (In Japanese)

We remain committed to contributing to the advancement of next-generation healthcare by sharing the results of our medical research with society.